Phase 2CompletedINTERVENTIONAL
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
ClinicalTrials.gov · NCT03311555 · Registry updated: 2024-03-19
- Condition / research focus
- Prostate Cancer
- Sponsor
- Andrew J. Armstrong, MD
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2018-03-28. Completion: 2022-12-22 (may be estimated). Results are posted in this registry.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Apalutamide (drug) — also listed as: ARN-509, JNJ-56021927
- Androgen deprivation (drug)
- Salvage radiation therapy (radiation)
- Docetaxel (drug)
Where the study takes place — 5 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- GU Research Network / Urology Cancer Center
Omaha, Nebraska, United States
Site recruitment: Not reported - Weill Cornell Medical Center
New York, New York, United States
Site recruitment: Not reported - Duke Cancer Center Cary
Cary, North Carolina, United States
Site recruitment: Not reported - Duke University Medical Center
Durham, North Carolina, United States
Site recruitment: Not reported - Wake Forest Univesity
Winston-Salem, North Carolina, United States
Site recruitment: Not reported